ArsenalBio is a programmable cell therapy company that offers CAR T-cell therapies for solid tumors.
ArsenalBio has raised $325.0M in total funding. The most recent round was Series C. The last funding was announced in September 2024.
ArsenalBio's investors include ARCH Venture Partners, Hitachi Ventures, Kleiner Perkins, Sixth Street, NVentures.
ArsenalBio is headquartered in South San Francisco, United States.
ArsenalBio is a programmable cell therapy company that offers CAR T-cell therapies for solid tumors.
ArsenalBio is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ArsenalBio — Funding & Investors." VCBacked, September 4, 2024, https://www.vcbacked.co/company/arsenalbio. Accessed July 19, 2026.
VCBacked. (2024). ArsenalBio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/arsenalbio
{{cite web |title=ArsenalBio — Funding & Investors |url=https://www.vcbacked.co/company/arsenalbio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated